ClinicalTrials.gg
RecruitingNCT06394752Updated May 1, 2024

UTERINE EVALUATION FOR THE IDENTIFICATION OF PATHOLOGY. This Study Will Compare the Intrauterine Pathology Detection Rate Between Standard of Care Hydrosonography, and a New Visual Saline Infusion Device Providing Direct Visualization of the Uterus.

An interventional study of Visual Saline Infusion and Hydrosonography in Hysteroscopy, Hysteroscopy Technique and Fertility Issues, sponsored by Center for Reproductive Health & Gynecology. Recruiting at 2 sites in 2 countries. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.

Primary conditionInfertility, FemaleRegistry: InfertilityReclassifiedWhy we changed it
Registry
Infertility — the first condition term the registry derived for this study.
ClinicalTrials.gg
Infertility, Female
Why
  1. The study's listed conditions name Infertility, Female, a narrower term within Infertility.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Center for Reproductive Health & Gynecology · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 24 under way, none of them phase 3. Infertility, Female · United States.

Planned enrollment
16th of 47
100 · median 50
Started
2024
with 5 others
No phase
30 of 65
11 open now
Primary completion
2025-05
later than 6 of 23 live
Registered
53rd of 65
by date

Among the 65 studies in Infertility, Female with a site in United States, this one is the 16th largest by planned enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2024, is one of 30 with no phase, reaches primary completion later than 6 of the 23 other live ones, and was the 53rd registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Infertility, Female with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, single center, multiple arm cohort study intended to compare the diagnostic accuracy of a Visual Saline Infusion Device (VSI) device, vs standard of care Hydrosonography in reproductive aged women to identify pathology in the uterus.

Read the detailed description

This is a prospective, single center, multiple arm cohort study intended to compare the diagnostic accuracy of a Visual Saline Infusion Device (VSI) device, vs standard of care Hydrosonography in reproductive aged women to identify pathology in the uterus.

Patients who are enrolled in the study will have a 1) Hydrosonography, and 2) Visual Saline Infusion procedure performed.

The Visual Saline Infusion Device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).

This study will recruit up to 100 women from a fertility center in Los Angeles.

03

Conditions studied

  • Hysteroscopy
  • Hysteroscopy Technique
  • Fertility Issues
  • Uterus Abnormal
  • Gynecology
  • Visualization
  • Infertility Female

Browse trials for

Keywords

  • hysteroscopy
  • fertility
  • gynecology
  • hydrosonography
  • uterine evaluation
  • uterine pathology
04

In context

Infertility, Female Reclassified

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

This is the only study on the registry with Center for Reproductive Health & Gynecology as lead sponsor.

Compared within Infertility, Female, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infertility. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients requiring a uterine cavity evaluation
  2. Premenopausal women between ages of 18-45

Exclusion criteria

Exclusion Criteria:

  1. Positive test or history of any of the following conditions:

1a. Chlamydial pelvic infection

1b. Gonorrheal pelvic infection. 2. Positive Pregnancy Test 3. IUD currently in place

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Visual Saline Infusion

    Visual Saline Infusion is intended to perform direct visual evaluation of the intrauterine space using a 2.7mm, steerable tip catheter with a camera.

    Device: Visual Saline Infusion

  • Active comparator
    Hydrosonography

    Hydrosonography is the standard of care for intrauterine evaluation. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus, and using abdominal ultrasound to detect intrauterine pathology.

    Device: Hydrosonography

Interventions

  • DeviceVisual Saline Infusion

    Visual Saline Infusion (VSI) is a new intrauterine imaging procedure to identify uterine pathology. The VSI device is a 2.7mm, steerable tip catheter with a camera and illumination at the distal end. The device is intended to evaluate the intrauterine space in an office based, outpatient setting using minimal volume of fluid (3-5cc's).

  • DeviceHydrosonography

    Hydrosonography is an ultrasound based intrauterine imaging technique with sensitivity and specificity ranging from 90% to 100% for identifying uterine pathology. It is performed by inserting a slim 2 mm catheter into the uterine cavity and infusing saline solution to expand the uterus and using abdominal ultrasound to visualize the uterus.

07

What researchers measure

Primary outcomes

  1. Intrauterine pathology detection rate with Hydrosonography

    The assessment will involve the examination of the intrauterine cavity for the presence of pathologies, including polyps, fibroids, adhesions, scar tissue, thickened endometrium, among others. The detection rate will be calculated as the ratio of the number of cases where abnormal pathologies are identified to the total number of cases examined.

    Time frame: Procedure of 2-5 minute duration

  2. Intrauterine pathology detection rate with Visual Saline Infusion

    The assessment will involve the examination of the intrauterine cavity for the presence of known pathologies, including polyps, fibroids, adhesions, scar tissue, thickened endometrium, among others. The detection rate will be calculated as the ratio of the number of cases where abnormal pathologies are identified to the total number of cases examined.

    Time frame: Procedure of approximately 2-5 minute duration

Secondary outcomes

  1. Visual detection quality score (1-10)

    The visual detection quality score will be assessed using a normalized scale ranging from 1 (indicating poor or no visualization) to 10 (indicating excellent visualization), with scores assigned based on the clarity and detail of the intrauterine images obtained during the examination.

    Time frame: Captured during procedure

  2. Fluid used during distention

    The volume of fluid used for distention of the uterus will be documented.

    Time frame: Captured during procedure

  3. Pain during procedure

    The research team will interview the Subject and record the level of pain experienced based on the Wong Baker pain scale

    Time frame: Collected on day of procedure

  4. Adverse events rate

    Anticipated and unanticipated adverse events will be documented

    Time frame: Day of procedure and 24-48 hours post to procedure

08

Study locations

1 of 2 sites recruiting
  • Center for Reproductive Health & Gynecology
    Beverly Hills, California 90007, United States
    Recruiting
    • Spencer Wendt · Contactinfo@reproductive.org · 310-360-7584
    • Sam Najmabadi, MD · Principal investigator
  • Punta Mita Fertility Center
    Corral Del Risco, Nayarit 63734, Mexico
    Not yet recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2025, 12 months after the start.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 12 months is below that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
May 1, 2024
StartActual
Apr 25, 2024
Primary completionEst.
May 1, 2025
CompletionEst.
Jul 30, 2025
Last update
May 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06394752
Lead sponsor
Center for Reproductive Health & Gynecology
Collaborators
Butterfly Biosciences, Inc
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Apr 25, 2024
Primary completion
May 1, 2025 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
May 1, 2024

Study contacts

Alexander Nadal, MBA
Contact
nadalalex@berkeley.edu
323-420-6343
Sam Najmabadi, MD
Contact
najmabadi@reproductive.org
310-360-7584
Sam Najmabadi, MD
principal investigator · Center for Reproductive Health & Gynecology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion